Intrabone Cord Blood Transplantation
Primary Purpose
Hematological Malignancies
Status
Unknown status
Phase
Phase 4
Locations
Spain
Study Type
Interventional
Intervention
Intrabone administration of umbilical cord blood
Sponsored by
About this trial
This is an interventional treatment trial for Hematological Malignancies
Eligibility Criteria
Inclusion Criteria:
- Hematological malignancies
- Indication of allogenic transplantation
- No suitable donor (related/unrelated)
- No suitable cord blood unit with enough cellularity for standard transplant
- Written informed consent
Exclusion Criteria:
- ECOG > 2
- Co-morbidities
- HIV positive serology
- Pregnancy or breastfeeding
- Psychiatric illness
Sites / Locations
- BMT Unit Hematology Department Hospital ClinicRecruiting
Arms of the Study
Arm 1
Arm Type
Experimental
Arm Label
Cord blood
Arm Description
Outcomes
Primary Outcome Measures
Kinetics of hematopoietic engraftment
Secondary Outcome Measures
Dynamics and chimerism of hematological engraftment
Full Information
NCT ID
NCT00838019
First Posted
February 5, 2009
Last Updated
February 5, 2009
Sponsor
Hospital Clinic of Barcelona
1. Study Identification
Unique Protocol Identification Number
NCT00838019
Brief Title
Intrabone Cord Blood Transplantation
Official Title
Pilot Study About Viability and Efficacy of Intrabone Administration of Umbilical Cord Blood for Allogeneic Stem Cell Transplantation
Study Type
Interventional
2. Study Status
Record Verification Date
February 2009
Overall Recruitment Status
Unknown status
Study Start Date
February 2009 (undefined)
Primary Completion Date
February 2011 (Anticipated)
Study Completion Date
February 2011 (Anticipated)
3. Sponsor/Collaborators
Name of the Sponsor
Hospital Clinic of Barcelona
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
The purpose of this study is to evaluate the viability of intrabone administration of umbilical cord blood as allogenic transplantation for the treatment of hematologic malignancies.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Hematological Malignancies
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 4
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
10 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
Cord blood
Arm Type
Experimental
Intervention Type
Procedure
Intervention Name(s)
Intrabone administration of umbilical cord blood
Intervention Description
Single administration
Primary Outcome Measure Information:
Title
Kinetics of hematopoietic engraftment
Time Frame
days 14, 21, 28 after administration
Secondary Outcome Measure Information:
Title
Dynamics and chimerism of hematological engraftment
Time Frame
days 14, 21, 28 after administration
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
60 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Hematological malignancies
Indication of allogenic transplantation
No suitable donor (related/unrelated)
No suitable cord blood unit with enough cellularity for standard transplant
Written informed consent
Exclusion Criteria:
ECOG > 2
Co-morbidities
HIV positive serology
Pregnancy or breastfeeding
Psychiatric illness
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Montserrat Rovira, MD
Phone
+34932275428
Email
mrovira@clinic.ub.es
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Montserrat Rovira, MD
Organizational Affiliation
Hospital Clinic of Barcelona
Official's Role
Principal Investigator
Facility Information:
Facility Name
BMT Unit Hematology Department Hospital Clinic
City
Barcelona
ZIP/Postal Code
08036
Country
Spain
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Montserrat Rovira, MD
Phone
+34932275428
Email
mrovira@clinic.ub.es
First Name & Middle Initial & Last Name & Degree
Montserrat Rovira, MD
12. IPD Sharing Statement
Learn more about this trial
Intrabone Cord Blood Transplantation
We'll reach out to this number within 24 hrs